Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases

SIMPLE SUMMARY: Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors are successful cancer therapeutics that impair DNA repair machinery, leading to an accumulation of DNA damage and consequently cell death. The shared underlying mechanisms driving malignancy and demyelinating disease, together with t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mekhaeil, Marianna, Dev, Kumlesh Kumar, Conroy, Melissa Jane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833351/
https://www.ncbi.nlm.nih.gov/pubmed/35158955
http://dx.doi.org/10.3390/cancers14030687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833351/
https://www.ncbi.nlm.nih.gov/pubmed/35158955
http://dx.doi.org/10.3390/cancers14030687

Ejemplares similares